Expert Interview
An updated view on JAKi prescribing patterns in autoimmune conditions
Ticker(s): PFEInstitution: Singing River Health System
- Board certified Rheumatologist in clinical practice for 18 years.
- Manages 1200 RA patients, 450 PsA patients, and 45-50 scleroderma patients in a non-academic community hospital system.
- Prescribes tofacitinib for RA, PsA, and UC.
To begin with, can you give us a general opinion on the results from ORAL surveillance, then we can dive a bit more into detail
Added By: wilson_adminCan you discuss the SoC for Rheumatoid arthritis, and how it has changed both before ORAL surveillance and after, wrt your prescribing patterns?
Added By: wilson_adminHas the class effect affected your prescribing patterns with other JAKs as well, or just Xeljanz?
Added By: wilson_adminwho do you feel are the right patients for Xeljanz? (examples: age, gender, disease progression, comorbidities, etc.) What about the other JAk inhibitors like Rinvoq and Olumiant?
Have the pharmaceutical companies changed their response to you in any way given this data? (Such as, presenting new patient safety data, increased focus on KOL interaction, new messaging, new detailing strategy, etc.)
Have you had any experience with Kevzara or Actemra in RA? Do you find you are using them more at all following ORAL surveillance?
Given the January 2021 safety data, who do you feel are the right patients for Xeljanz? (examples: age, gender, disease progression, comorbidities, etc.) What about the other JAk inhibitors like Rinvoq and Olumiant?
Can you discuss more about the SoC, lines of treatment for psoriatic arthritis both before and after ORAL surveillance?
Added By: wilson_adminCan you discuss more about the SoC, lines of treatment for ulcerative colitis, where this isn't as many options to begin with?
Added By: wilson_adminIf the safety data has impacted your prescribing habits with Xeljanz and or the JAK inhibitor class, what do manufacturers need to do to demonstrate safety to increase confidence in the drug?
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
